The company relies on the next generation of immune cell therapy technology to develop and research NK and CAR-NK immune cell products.
ABOUT
Beijing Gene MiNK Biotechnology CO.LTD.
Beijing Gene MiNK Biotechnology CO.LTD. is a biopharmaceutical innovation enterprise whose main research object is immune cells. Established in December 2021. The founders are two returnees from studying in the United States. Angel round, seed round, and A round financing have been completed. The company currently has 6 NK and CAR-NK cell products. Two have obtained IND approvals from the China (CDE) and US (FDA) National Drug Administration. Indications include: leukemia, lung cancer, ovarian cancer, breast cancer and other advanced tumor diseases, as well as various autoimmune diseases. The company has been authorized 7 invention patents and is applying for 3 patents, including 2 US patents. The patent content covers the entire process of NK cell and CAR-NK cell preparation. It solves the industry pain points and difficulties of low NK cell expansion multiplicity and low CAR-NK cell transduction rate. The company has completely independent intellectual property rights, there is no infringement of intellectual property rights, and will not be "stuck neck". At present, our company's technical level is among the top in China and internationally.
R&D, production, and quality control personnel, a complete team covering the entire cell product production process.
The Beijing R&D center has a total area of 500 square meters, including: 3 C+A grade cell preparation rooms, 1 molecular room, 1 quality inspection room, and 1 positive detection room. It is fully equipped to conduct IIT trials.
Internationally advanced instruments and equipment can complete the entire process from R&D to cell preparation to final quality inspection.
In June 2023, the R&D of multiple myeloma BCMA-CAR-NK cell products was completed, and the treatment of 3 patients (IIT trial) achieved significant therapeutic effects.
Angel and Seed Round Financing
Obtained Invention Patents
Laboratory Area
IIT Trial Treatment Effect
Continuous recognition from the industry
Yongfeng Liu Founder
Researcher at Albany Medical Center, New York State, USA
PhD in Physiology, University of Otago, New Zealand
- Before returning to China, he worked at the Department of Molecular Cell Biology, Albany Medical Center, New York State, USA, as an independent researcher at Albany Medical Center, USA.
- Nearly 20 years focusing on protein structure, function and cell immunotherapy. He has a unique and profound understanding of CAR-T, CAR-NK modification, iPSC differentiation of T, NK cells, red blood cells, cardiomyocytes and other cells.
- Priority discovery of proteins regulating the function of epithelial sodium channels through ubiquitination.
- Priority elucidation of the pathogenesis of DNA demethylase in atherosclerosis.
Zhihua Lu Founder
Visiting scholar at Stanford University, USA
Doctor of Medicine, Peking Union Medical College
- Visiting scholar at Stanford University, USA, chief physician and professor of a top three hospital in China, focusing on cancer diagnosis and treatment, cell immunotherapy, and stem cell therapy.
- The first in China to complete the preparation of universal CAR-T products by combining AAV homologous recombination technology with CRISPR gene editing technology, and submitted two invention patents.
- Combining CRISPR gene editing technology, focusing on the development of CAR-NK cell preparation platform and iPSC-induced differentiation of multiple cell technology platforms. Multiple products such as NK, CAR-NK, iPSC-CAR-NK, and NKCE have been developed and entered the process confirmation stage.
Online Message
Please leave your needs and suggestions, and we will contact you as soon as possible!
Quick Navigation
Contact Information
Room 401, Unit 1, Building 2, No. 25, Jinghai Fourth Road, Beijing Economic and Technological Development Area, Beijing (Beijing Pilot Free Trade Zone, High-end Industrial Zone, Yizhuang Group)
Beijing Gene MiNK Biotechnology Co., Ltd